{"slideshow_credits": null, "snippet": "In two early stage studies, Bristol-Myers Squibb&#8217;s nivolumab and Merck&#8217;s pembrolizumab shrank tumors in patients with Hodgkin&#8217;s lymphoma.", "abstract": "Research published online by New England Journal of Medicine Researchers finds that drugs that free body\u2019s immune system to fight cancer, known as PD-1 inhibitors, have shown strong preliminary results in treating Hodgkin\u2019s lymphoma, shrinking tumors in well over half of patients who have exhausted many other treatment options.", "section_name": "Business Day", "print_page": "30", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}], "original": "By ANDREW POLLACK", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/12/07/business/cancer-drugs-that-free-brake-on-immune-system-show-promise-for-hodgkins.html", "lead_paragraph": "In two early stage studies, Bristol-Myers Squibb&#8217;s nivolumab and Merck&#8217;s pembrolizumab shrank tumors in patients with Hodgkin&#8217;s lymphoma.", "headline": {"main": "Cancer Drugs That Free Brake on Immune System Show Promise for Hodgkin&#8217;s", "print_headline": "Cancer Drugs That Free Brake on Immune System Show Promise for Hodgkin\u2019s"}, "_id": "5483a24638f0d80df4fa3e55", "word_count": "606", "multimedia": [], "pub_date": "2014-12-07T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "New England Journal of Medicine", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Hodgkin's Lymphoma", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Cancer", "is_major": "N", "rank": "5"}, {"name": "organizations", "value": "Bristol Myers Squibb Company", "is_major": "N", "rank": "6"}, {"name": "organizations", "value": "Merck & Company Inc", "is_major": "N", "rank": "7"}], "blog": [], "subsection_name": null, "type_of_material": "News"}